{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:14:59Z","timestamp":1784603699169,"version":"3.55.0"},"reference-count":39,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Trichomoniasis, caused by <jats:italic>Trichomonas vaginalis<\/jats:italic> (TV), is the most common curable sexually transmitted infection worldwide. Current guidance in the UK is to treat TV with a nitroimidazole antibiotic. The high prevalence of TV, high rate of antibiotic resistance and limited tolerability to nitroimidazoles suggest that alternative treatment regimens are needed. Intravaginal boric acid (BA) has been used safely for the treatment of candida vulvovaginitis and bacterial vaginosis, and in vitro studies suggest BA is active against TV. We review the evidence for the efficacy of BA in patients with TV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MEDLINE, EMBASE, CINAHL, AMED, HMIC and BNI and Grey literature databases, The Cochrane Library, Trial Registers, conference abstracts and proceedings were searched. Inclusion criteria were women aged 16 years or over with microbiological confirmation of TV infection and using BA as treatment. There were no restrictions on language, publication date or study design. The in vitro evidence for BA activity against TV was also reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No randomised controlled trials or case series were found. Four case reports demonstrated TV clearance with BA using a variety of dose regimens (dose 600\u2009mg alternate nights to 600\u2009mg two times per day; duration 1\u20135 months). In vitro studies suggest that BA has activity against TV which is independent of its effect on pH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Further evaluation of BA for the treatment of uncomplicated TV is required, but it may be useful when therapeutic options are limited. If shown to be safe and effective, intravaginal BA might provide a well-tolerated alternative anti-infective treatment which reduces community exposure to systemic antibiotics.<\/jats:p><\/jats:sec>","DOI":"10.1136\/sextrans-2017-053343","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T17:15:17Z","timestamp":1512839717000},"page":"574-577","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Intravaginal boric acid: is it an alternative therapeutic option for vaginal trichomoniasis?"],"prefix":"10.1136","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1706-357X","authenticated-orcid":false,"given":"Nicola","family":"Thorley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,12,9]]},"reference":[{"key":"2020050723340599000_94.8.574.1","unstructured":"World Health Organisation DoRHaR. Prevalenceand incidence of selected sexually transmitted infections chlamydiatrachomatis, neisseria gonorrhoeae, syphilis and trichomonasvaginalis: methods and results used by WHO to generate 2005. 2015. http:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/9789241502450\/en\/"},{"key":"2020050723340599000_94.8.574.2","doi-asserted-by":"publisher","DOI":"10.1086\/522532"},{"key":"2020050723340599000_94.8.574.3","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2014-051514"},{"key":"2020050723340599000_94.8.574.4","doi-asserted-by":"publisher","DOI":"10.1177\/0956462414525947"},{"key":"2020050723340599000_94.8.574.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2009.08.004"},{"key":"2020050723340599000_94.8.574.6","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.2.300"},{"key":"2020050723340599000_94.8.574.7","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199707000-00009"},{"key":"2020050723340599000_94.8.574.8","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199707000-00008"},{"key":"2020050723340599000_94.8.574.9","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2003.005124"},{"key":"2020050723340599000_94.8.574.10","first-page":"743","article-title":"Treatment of vaginal trichomoniasis. Single, 2-gram dose of metronidazole as compared with a seven-day course","volume":"27","author":"Aubert","year":"1982","journal-title":"J Reprod Med"},{"key":"2020050723340599000_94.8.574.11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.1998.00273.x"},{"key":"2020050723340599000_94.8.574.12","doi-asserted-by":"publisher","DOI":"10.3201\/eid1806.111590"},{"key":"2020050723340599000_94.8.574.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00814-06"},{"issue":"Suppl 1","key":"2020050723340599000_94.8.574.14","doi-asserted-by":"crossref","first-page":"A9.2","DOI":"10.1136\/sextrans-2016-052718.23","article-title":"O024\u2005Trichomonas vaginalis\u2013treatment and test of cure analysis in a GUM clinic population","volume":"92","author":"Bathgate","year":"2016","journal-title":"Sex Transm Infect"},{"key":"2020050723340599000_94.8.574.15","unstructured":"Bradic M , Secor WE , Conrad MD , et al . Distribution of drug resistance and its genetic basis in global isolates of trichomonas vaginalis. Am J Trop Med Hyg 2012;87(5 Suppl 1)."},{"key":"2020050723340599000_94.8.574.16","doi-asserted-by":"publisher","DOI":"10.1071\/SH09038"},{"key":"2020050723340599000_94.8.574.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2012.10.004"},{"key":"2020050723340599000_94.8.574.18","unstructured":"Department of Health. Five year antimicrobial resistance strategy 2013 to 2018, 2015. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/244058\/20130902_UK_5_year_AMR_strategy.pdf"},{"key":"2020050723340599000_94.8.574.19","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.783-793.2004"},{"key":"2020050723340599000_94.8.574.20","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3181b08456"},{"key":"2020050723340599000_94.8.574.21","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2010.2708"},{"key":"2020050723340599000_94.8.574.22","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1469"},{"issue":"Suppl 1","key":"2020050723340599000_94.8.574.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/myc.12292","article-title":"Guideline: vulvovaginal candidosis (AWMF 015\/072), S2k (excluding chronic mucocutaneous candidosis)","volume":"58","author":"Mendling","year":"2015","journal-title":"Mycoses"},{"key":"2020050723340599000_94.8.574.24","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-200305000-00024"},{"key":"2020050723340599000_94.8.574.25","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.111938"},{"key":"2020050723340599000_94.8.574.26","doi-asserted-by":"publisher","DOI":"10.1067\/S0002-9378(03)00726-9"},{"key":"2020050723340599000_94.8.574.27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0002-9378(16)32581-9","article-title":"Treatment of vulvovaginal candidiasis with boric acid powder","volume":"141","author":"Van Slyke","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"2020050723340599000_94.8.574.28","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000203"},{"key":"2020050723340599000_94.8.574.29","doi-asserted-by":"publisher","DOI":"10.1155\/S1064744998000386"},{"key":"2020050723340599000_94.8.574.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(16)32714-1"},{"key":"2020050723340599000_94.8.574.31","unstructured":"Thorley NL , Ross J . Systematic review of intravaginal boric acid as treatment for vaginal trichomoniasis in women PROSPERO2016. 2017. https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?ID=CRD42016043347"},{"key":"2020050723340599000_94.8.574.32","doi-asserted-by":"crossref","unstructured":"BASHH. BASHH Conference oxford abstract presentations. Sex Transm Infect 2016;92(Suppl 1).","DOI":"10.1136\/sextrans-2016-052837"},{"key":"2020050723340599000_94.8.574.33","unstructured":"BASHH. BASHH abstract presentations. BASHH spring conference 2015. Glasgow: BASHH, 2015."},{"key":"2020050723340599000_94.8.574.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2007.06.008"},{"key":"2020050723340599000_94.8.574.35","doi-asserted-by":"publisher","DOI":"10.1071\/SH11114"},{"issue":"4 suppl","key":"2020050723340599000_94.8.574.36","first-page":"316","article-title":"Current therapy of vulvovaginitis","volume":"8","author":"Rein","year":"1981","journal-title":"Sex Transm Dis"},{"key":"2020050723340599000_94.8.574.37","doi-asserted-by":"crossref","unstructured":"Zeron Mullins M , Trouton KM . BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial. Trials 2015;16:315. doi:10.1186\/s13063-015-0852-5","DOI":"10.1186\/s13063-015-0852-5"},{"key":"2020050723340599000_94.8.574.38","doi-asserted-by":"crossref","unstructured":"Backus KV , Muzny CA , Beauchamps LS . Trichomonas vaginalis treated with boric acid in a metronidazole allergic female. Sexually transmitted diseases 2016.","DOI":"10.1097\/OLQ.0000000000000559"},{"key":"2020050723340599000_94.8.574.39","unstructured":"CDC. 2015 Sexually transmitted diseases guidelines. 2016. https:\/\/www.cdc.gov\/std\/tg2015\/trichomoniasis.htm"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2017-053343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T10:19:59Z","timestamp":1601115599000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2017-053343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,9]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,11,22]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1136\/sextrans-2017-053343"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2017-053343","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,9]]}}}